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In the Western world, 30-40 % of the adult population suffers from hypertension. The prevalence is expected to increase with the aging population. Sixty-fi ve percent of patients over 60 years of age are affected by hypertension. It is thought to be the greatest risk factor for cardiovascular disease. Renal sympathetic efferent and afferent nerves are recognized as critical in the hypertensive disease process and represent an important therapeutic target. From the 1930s to 1950s, investigators performed surgical interruption of the sympathetic pathway and effectively lowered the pressure signifi cantly in patients, but there were complications that precluded the continued application of this technique at the same time that effective drug regimens evolved.
Recently, renal denervation has been reborn as a catheter technique utilizing the proximity of the renal nerves to the renal arteries utilizing various forms of energy or injections. This technique has been effective in treating resistant hypertension in as many as 85 % of patients. The ability to perform this transcatheter technique has the potential to cause a paradigm shift in cardiovascular care. Resistant hypertension is defi ned as blood pressure persistently above goal despite the use of antihypertensive medications from ≥3 drug classes. These patients face worse cardiovascular outcomes and systemic hypertension-related complications, for which there is no viable treatment option. For example, poorly controlled hypertension can increase stroke rate by 50 %.
The new percutaneous approach, based on the concept of an old surgical technique, may be a true game changer for treating patients with not only hypertension but also renal insufficiency, congestive heart failure, diabetes mellitus, obesity, sleep apnea, and glucose intolerance. Given the enormous market for this treatment approach and the rapidly compounded annual growth rate, an estimated 60 companies are pursuing technologies to achieve RDN with equivalent or superior approaches. This treatment is moving so quickly and has been thought effective enough in its early stages that the European Society of Cardiology (ESC) has issued a consensus statement describing patients that are appropriate to be screened for this therapy. The whole fi eld of renal arterial based renal denervation dealt a serious blow with the publication of the Symplicity HTN-3 6-month data. This blinded trial did not show signifi cant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control (Funded by Medtronic: SYMPLICITY HTN-3 ClinicalTrials.gov, number, NCT01418261) [1] . After 6 months, offi ce systolic blood pressure decreased from baseline to a similar extent in the renal-denervation and sham-procedure groups ( P < 0.001) for both comparisons of the change from baseline); the difference in the change in blood pressure between the two groups was a paltry −2.39 mmHg. In addition, a prespecifi ed difference in 24-h ambulatory systolic pressure of only 2 mmHg was not met. Thus, in the SYMPLICITY HTN-3 STUDY, renal denervation had no signifi cant effect on offi ce or 24-h ambulatory systolic blood pressure, fi ndings that contradict most published data on renal denervation. While renal denervation lowered blood pressure by an average of 14.1 mmHg, it was not statistically signifi cant when compared to the sham treatment. Patients receiving no treatment may experience Hawthorne effect, believing they had received the treatment, resulting in an 11.7 mmHg reduction. The trial used the fi rst-generation Medtronic Symplicity catheter, which uses a single electrode that must be maneuvered into specifi c positions for ablations that last about a minute each. The procedure is similar to cardiac Pref ace vi ablations to isolate arrhythmia-causing cardiac tissue. Electrophysiology ablations are sometimes diffi cult to perform or have mixed outcomes, depending on several factors, including catheter pressure applied, duration of the ablation and the ability of the operator to connect all the dots between ablation points to prevent the transmission of electrical signals across the scarred areas. Further studies in rigorously designed trials will be needed to confi rm the results of the earlier trials. The 5-year results of this study will be fascinating and some groups had a near signifi cant benefi t compared to medical therapy. Results were maintained in prespecifi ed subgroup analysis, although non-African Americans tended to benefi t from renal denervation more so than African Americans ( P = 0.09). A number of limitations were identifi ed by the study's authors, and also reviewed by the discussion panel after the presentation. Blood levels of antihypertensive medications were not obtained, so drug adherence was not directly measured. The large and signifi cant change over time in both groups may have been related to the placebo effect, or it may be that study participants in both arms achieved improved medication compliance after enrollment in the study. Further, there is no commonly accepted and easily obtained measure of denervation of the renal sympathetic system, so it is possible that renal denervation did not occur, although the study authors could confi rm that the appropriate energy had been delivered by the device.
Experts have weighed in as to why this study showed different results than other studies, particularly in Europe. A large concern was operator's inexperience with denervation (they were all experienced interventional cardiologists) another fl aw in the trial design was that no method was used to monitor the effi cacy of each denervation procedure, an easy decision because there is still no proven way to measure denervation effi cacy during the procedure. In the fi rst clinical study of renal denervation, in a series of 45 patients treated at fi ve centers in Australia and Europe reported just 5 years ago ( Lancet 2009;373:1275-81), Dr. Esler, a lead investigator for that study, and his associates carefully tested the effi cacy of denervation in ten patients by measuring the direct effect of successful denervation and reduction of renal norepinephrine spillover. They reported that, in those ten patients, renal denervation cut norepinephrine spillover by an average of 47 %, which correlated with an average reduction in systolic blood pressure of 22 mmHg after 6 months.
Because of the aging of the population and rising rates of obesity, hypertension is increasing in prevalence worldwide. Approximately 10 % of patients with diagnosed hypertension have resistant hypertension, defi ned as a systolic blood pressure of 140 mmHg or higher despite adherence to at least three maximally tolerated doses of antihypertensive medications from complementary classes, included a diuretic at an appropriate dose. The sympathetic nervous system -in particular, sympathetic cross-talk between the kidneys and the brain -appears to play an important role in resistant hypertension.
In spite of this recent published study, very limited data has been published on preclinical and clinical experiences with these new devices, and the future of this fi eld is controversial. Other new approaches, including less invasive and outpatient-based therapies, may or may not be effective. Unfortunately, during the last 10 years, very few new antihypertensive agents have reached the market and no new therapeutic class has really emerged if one considers renin inhibitors as members of drugs inhibiting the renin-angiotensin system (RAS). Thus, the actual strategy to control blood pressure in hypertension relies on the use of three major classes of antihypertensive drugs, i.e. , blockers of the RAS, calcium channel blockers (CCBs), and diuretics (D) as reported in the last 2013 hypertension guidelines of the European Society of Hypertension and European Society of Cardiology. One very important issue with any study of hypertensive patients, including HTN-3, is that there was no confi rmation of medication adherence. More than 50 % of patients with resistant hypertension are known to be nonadherent to medications. There was no direct measurement to confi rm that the renal nerves were in fact denervated by the procedure, because there is no test that can be easily performed in a large trial. However, the Symplicity catheter system allowed confi rmation of energy delivery, and the presence of angiographic notching indicated a biologic effect of energy delivery on the artery. Finally, the results of this trial are specifi c to the catheter tested and cannot necessarily Preface vii be generalized to other denervation systems. We shall await further data. This textbook is aimed to provide an overview of the fi eld, to describe the preclinical and clinical experiences with the most prominent technologies in the pipeline, and to provide insights regarding the possible directions this fi eld may be heading.
I was pleased to have been introduced to Victoria John from Springer Publishing who agreed with me that a textbook describing this new treatment would be a welcome addition. My co-editors are two world renowned leaders in the fi eld including Horst Sievert from Germany and Markus Schlaich from Australia. We have attempted to pull together the experts in the fi eld in our textbook and are proud to say everyone we invited to contribute agreed to be represented in the textbook. We have described most of the current devices and approaches, and we hope to give the reader a snapshot of where things are available at this time.
I would like to thank Victoria and my co-editors Horst Sievert and Markus Schlaich, along with our co-authors without which the textbook would not have been possible. As with other textbooks I have edited, I will donate all my royalties to Johns Hopkins Hospital where I trained. I also wish to dedicate this book to the Phoenix Heart Center, St. Luke's Medical Center and my daughter Alexandra and wife Shari. Special thanks to Peggy Layman for putting up with everything she needs to deal with not only this publication, but everything involved with interacting with me.
We hope the reader will fi nd this textbook a springboard for study and advancement of this new, exciting fi eld. 
